(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Merck-Hengrui Pharma Deal Announced Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug ...

The deal will give the U.S. drugmaker access to an experimental heart disease drug. “The companies ... Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop ... risk factor for atherosclerotic cardiovascular disease, affecting as many as one in five adults globally ...

Per the terms of the deal, Merck will acquire the global rights (excluding Greater China ... are a significant risk factor for cardiovascular disease like heart attack and stroke.

Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion ...